Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Lurbinectedin
Synonyms
Therapy Description

Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lurbinectedin Zepzelca PM01183 Chemotherapy - Alkylating 18 Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01405391 Phase I Lurbinectedin Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks Completed USA 0
NCT05734066 Phase Ib/II Lurbinectedin Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (EMERGE 101) Recruiting USA | CAN 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT05918640 Phase Ib/II Lurbinectedin Lurbinectedin in FET-Fused Tumors (LiFFT) Recruiting USA 0
NCT05740566 Phase III Lurbinectedin Topotecan Amrubicin Tarlatamab Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 19
NCT06217536 Phase Ib/II Lurbinectedin Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Not yet recruiting USA 0
NCT06228066 Phase II Avelumab + Lurbinectedin Lurbinectedin Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Recruiting USA 0
NCT01525589 Phase II Lurbinectedin A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Completed USA | ESP 0


Additional content available in CKB BOOST